Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.59 |
| ▸ | CTSS | P25774 | 5/20 | 0.59 |
| ▸ | PPARA | Q07869 | 9/20 | 0.52 |
| ▸ | PPARG | P37231 | 8/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7857819 | 1.00 | CTSK (0.59) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL13744415 | 1.00 | CTSK (0.59) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL5007433 | 0.92 | CTSK (0.57) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL5007432 | 0.92 | CTSK (0.57) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL31341247 | 0.88 | CTSK (0.55) | CTSKCTSSPPARAPPARG | |
| SCHEMBL23705756 | 0.88 | CTSK (0.58) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL12305799 | 0.88 | PPARA (0.62) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL21409154 | 0.88 | PPARA (0.62) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL8316046 | 0.88 | CTSK (0.58) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL3773563 | 0.88 | CTSK (0.58) | CTSKCTSSPPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2025-11-18 | — | — | US | disclosed |
| US-20240043470-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | UNIV CORNELL (US) | 2024-02-08 | — | — | US | disclosed |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220324907-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE | 2022-10-13 | — | — | US | disclosed |
| CN-112165938-A | Factor XIIA inhibitors | 利兹大学 | 2021-01-01 | — | — | CN | disclosed |
| EP-3694508-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | Cornell University (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019075259-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | CORNELL UNIVERSITY (US) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043470-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB3 | CTSK 1101/4885CTSS 640/4885PPARA 4669/4885 |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | CTSK 1101/4885CTSS 640/4885PPARA 4669/4885 |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | CTSK 1101/4885CTSS 640/4885PPARA 4669/4885 |
| US-20220324907-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB3 | CTSK 1101/4885CTSS 640/4885PPARA 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.